Treace Medical investors face securities fraud class action lawsuit deadline.
PorAinvest
martes, 3 de junio de 2025, 8:37 am ET1 min de lectura
TMCI--
The lawsuit alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
1. Competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System.
2. As a result, Treace Medical's revenue declined, and the company needed to accelerate its plans to offer a product that was an alternative to osteotomy.
3. Defendants' positive statements about Treace Medical's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
When the true details entered the market, the lawsuit claims that investors suffered damages. The Rosen Law Firm, which represents investors in the class action, encourages investors to select qualified counsel with a proven track record in securities class actions [1].
Investors with losses in excess of $100,000 have the opportunity to serve as lead plaintiffs and direct the litigation. The deadline to move the Court for this role is June 10, 2025. Investors do not have to participate in the case to be eligible for a recovery. They can remain as absent class members [2].
The Rosen Law Firm has a history of success in securities class actions and has recovered hundreds of millions of dollars for investors. For more information, visit https://rosenlegal.com/submit-form/?case_id=38284 or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.
References:
[1] https://www.marketscreener.com/quote/stock/TREACE-MEDICAL-CONCEPTS-I-121986239/news/TMCI-Deadline-TMCI-Investors-with-Losses-in-Excess-of-100K-Have-Opportunity-to-Lead-Treace-Medical-50117835/
[2] https://www.morningstar.com/news/business-wire/20250601707129/tmci-deadline-rosen-law-firm-urges-treace-medical-concepts-inc-nasdaq-tmci-stockholders-with-losses-in-excess-of-100k-to-contact-the-firm-for-information-about-their-rights
Bernstein Liebhard LLP reminds investors of an upcoming deadline for a securities fraud class action lawsuit against Treace Medical Concepts, Inc. (NASDAQ: TMCI). The lawsuit was filed in the US District Court for the Middle District of Florida on behalf of investors who purchased TMCI shares between May 8, 2023 and May 7, 2024. Those who purchased shares during this period and lost money are encouraged to visit the Treace Medical Concepts, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030.
Investors in Treace Medical Concepts, Inc. (NASDAQ: TMCI) are reminded of an upcoming deadline for a securities fraud class action lawsuit. The lawsuit, filed in the US District Court for the Middle District of Florida, targets investors who purchased TMCI shares between May 8, 2023, and May 7, 2024. Those who purchased shares during this period and experienced losses are encouraged to visit the Treace Medical Concepts, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030.The lawsuit alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
1. Competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System.
2. As a result, Treace Medical's revenue declined, and the company needed to accelerate its plans to offer a product that was an alternative to osteotomy.
3. Defendants' positive statements about Treace Medical's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
When the true details entered the market, the lawsuit claims that investors suffered damages. The Rosen Law Firm, which represents investors in the class action, encourages investors to select qualified counsel with a proven track record in securities class actions [1].
Investors with losses in excess of $100,000 have the opportunity to serve as lead plaintiffs and direct the litigation. The deadline to move the Court for this role is June 10, 2025. Investors do not have to participate in the case to be eligible for a recovery. They can remain as absent class members [2].
The Rosen Law Firm has a history of success in securities class actions and has recovered hundreds of millions of dollars for investors. For more information, visit https://rosenlegal.com/submit-form/?case_id=38284 or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.
References:
[1] https://www.marketscreener.com/quote/stock/TREACE-MEDICAL-CONCEPTS-I-121986239/news/TMCI-Deadline-TMCI-Investors-with-Losses-in-Excess-of-100K-Have-Opportunity-to-Lead-Treace-Medical-50117835/
[2] https://www.morningstar.com/news/business-wire/20250601707129/tmci-deadline-rosen-law-firm-urges-treace-medical-concepts-inc-nasdaq-tmci-stockholders-with-losses-in-excess-of-100k-to-contact-the-firm-for-information-about-their-rights

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios